rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Neuropace, Inc.

NPCE · Nasdaq

Health CareMedical DevicesNot moving yetNeurotech

NPCE stood above a rising 150-day average in 33 of the last 52 weekly readings, and has been out of that trend for the last 13 weeks. It is 18.8% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 13
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$799K
Officials’ trades on record
0
Institutions holding
111 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 33 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$48.8M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
Martha MorrellCHIEF MEDICAL OFFICERsold25,000at $15.9715 Dec 2025filed 4 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders111+3 on the quarter
New · exited21 · 18
Reported value$421.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Polar Capital Holdings Plcunchanged · filed 14 Aug 20263,298,104$52.4M00.0%
Soleus Capital Management, L.P.reduced · filed 11 Aug 20262,911,122$46.3M-21,085−0.7%
First Light Asset Management, LLCadded · filed 14 Aug 20262,861,167$45.5M+401,201+16.3%
MORGAN STANLEYadded · filed 13 Aug 20262,654,391$42.2M+87,552+3.4%
BlackRock, Inc.added · filed 7 Aug 20262,477,603$39.4M+131,270+5.6%
ORBIMED ADVISORS LLCreduced · filed 14 Aug 20261,505,125$23.9M-591,402−28.2%
Driehaus Capital Management LLCreduced · filed 14 Aug 20261,447,391$23.0M-4,220−0.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,227,072$19.5M+103,361+9.2%
DEUTSCHE BANK AG\added · filed 7 Aug 2026938,919$14.9M+6,829+0.7%
ARMISTICE CAPITAL, LLCunchanged · filed 14 Aug 2026692,000$11.0M00.0%
31 Mar 2023 – 30 Jun 2026
2265108Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Martha Morrell Company insiderCHIEF MEDICAL OFFICER · last 24 Sep 20260 · 16
Patrick F. Williams Company insiderChief Financial Officer · last 20 Sep 20260 · 0
Joel Becker Company insiderCHIEF EXECUTIVE OFFICER · last 3 Sep 20260 · 0
Frank M. Fischer Company insiderDirector · last 19 Jun 20261 · 0
Rakhi Kumar Company insiderDirector · last 19 Jun 20260 · 0
Uri Geiger Company insiderDirector · last 19 Jun 20260 · 0
Lisa Andrade Company insiderDirector · last 5 Jun 20260 · 0
R. Scott Huennekens Company insiderDirector · last 5 Jun 20260 · 0
Renee Ryan Company insiderDirector · last 5 Jun 20260 · 0
Joseph Lacob Company insiderDirector · last 20 Mar 20260 · 0
Rebecca Kuhn Company insiderCHIEF FINANCIAL OFFICER · last 3 Jun 20250 · 0
ORBIMED ADVISORS LLC Company insider10% owner · last 14 May 20250 · 8

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

Awards1
Total$37K
Latest17 Dec 2025

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202577.2%
Operating profit marginFY 2025 · to 31 Dec 2025-16.3%
Free cash flow marginFY 2025 · to 31 Dec 2025-11.3%
Return on capital employedFY 2025 · to 31 Dec 2025-18.6%
Debt to equityFY 2025 · to 31 Dec 20253.09×
Research spendFY 2025 · to 31 Dec 202527.9%
Share count trendFY 2025 · to 27 Feb 20260.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$21.7M
Free cash flowFY 2025 · to 31 Dec 2025−$11.3M

Analyst forecasts

No analyst forecasts yet.